These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 9072602

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE.
    Eur Urol; 1997 May; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
    Wada Y, Kikuchi K, Takahashi W, Honda J, Nakanishi J, Matsumoto K, Kuwahara T, Kai N, Kikukawa H, Ueda S.
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305
    [Abstract] [Full Text] [Related]

  • 31. Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer.
    Van Poppel H, Werbrouck PW, Baert L.
    Acta Urol Belg; 1990 Jan; 58(4):89-95. PubMed ID: 2093302
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K, Miura N, Azuma K, Karashima T, Kasahara K, Nakatsuzi H, Hashine K, Sumiyoshi Y.
    Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Clinical course of hormone refractory cancer of the prostate].
    Morote J, Vila J, López-Pacios MA, De Torres JA, Soler-Roselló A.
    Actas Urol Esp; 1992 Oct; 16(9):722-5. PubMed ID: 1283286
    [Abstract] [Full Text] [Related]

  • 39. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.
    Garcia JA, Weinberg V, Small EJ.
    Clin Prostate Cancer; 2005 Sep; 4(2):113-7. PubMed ID: 16197612
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.